Evidence map›Paper›PMID 32808077›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2021

False positive PSMA PET for tumor remnants in the irradiated prostate and other interpretation pitfalls in a prospective multi-center trial.

Wolfgang P Fendler, Jeremie Calais, Matthias Eiber, Jeffrey P Simko, John Kurhanewicz, Romelyn Delos Santos, Felix Y Feng, Robert E Reiter, Matthew B Rettig, Nicholas G Nickols and 8 more

2 registry-linked trialsOpen access · hybridAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 27 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 2 pooled it
4.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02940262 phase3completednot on this map

68Ga-PSMA PET/CT for Detection of Recurrent Prostate Cancer After Initial Therapy

TypeinterventionalSponsorJonsson Comprehensive Cancer CenterRan2016 to 2021Enrolled1,138ConditionsProstate Adenocarcinoma, Recurrent Prostate CarcinomaArmsGallium Ga 68 Gozetotide, Laboratory Biomarker Analysis, Positron Emission Tomography
NCT03353740 phase3completednot on this map

Gallium-68 PSMA-11 PET Imaging in Patients With Biochemical Recurrence

TypeinterventionalSponsorThomas HopeRan2017 to 2020Enrolled346ConditionsProstate CancerArmsGa-68 labeled PSMA-11 PET
3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 55 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Synthesis, preclinical, and initial clinical evaluation of integrin αEuropean journal of nuclear medicine and molecular imaging · 2024
    Article
  9. Review
  10. PredictingAcademic radiology · 2024
    Article
  11. Review
  12. PSMA PET-CT in the Diagnosis and Staging of Prostate Cancer.Diagnostics (Basel, Switzerland) · 2022
    Review
  13. Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022
    Article
  14. Article
  15. Article
  16. A Comprehensive Assessment ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022
    Article
  17. Influences on PET Quantification and Interpretation.Diagnostics (Basel, Switzerland) · 2022
    Review
  18. Article
  19. PSMA PET in Imaging Prostate Cancer.Frontiers in oncology · 2022
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 2 institutions in 2 countries.

Wolfgang P FendlerDepartment of Molecular and Medical Pharmacology, Ahmanson Translational Imaging Division, University of California Los Angeles, Los Angeles, CA, USA. wolfgang.fendler@uk-essen.de.
Jeremie CalaisDepartment of Molecular and Medical Pharmacology, Ahmanson Translational Imaging Division, University of California Los Angeles, Los Angeles, CA, USA.
Matthias EiberDepartment of Molecular and Medical Pharmacology, Ahmanson Translational Imaging Division, University of California Los Angeles, Los Angeles, CA, USA.
Jeffrey P SimkoDepartment of Anatomic Pathology and Department of Urology, University of California San Francisco, San Francisco, CA, USA.
John KurhanewiczDepartment of Urology, University of California San Francisco, San Francisco, CA, USA.
Romelyn Delos SantosDepartment of Urology, University of California San Francisco, San Francisco, CA, USA.
Felix Y FengDepartment of Urology, University of California San Francisco, San Francisco, CA, USA.
Robert E ReiterDepartment of Urology, UCLA Medical Center, University of California Los Angeles, Los Angeles, CA, USA.
Matthew B RettigDepartment of Urology, UCLA Medical Center, University of California Los Angeles, Los Angeles, CA, USA.
Nicholas G NickolsDepartment of Urology, UCLA Medical Center, University of California Los Angeles, Los Angeles, CA, USA.
Amar U KishanDepartment of Radiation Oncology, University of California Los Angeles, Los Angeles, CA, USA.
PSMA PET Reader Group
Roger SlavikDepartment of Molecular and Medical Pharmacology, Ahmanson Translational Imaging Division, University of California Los Angeles, Los Angeles, CA, USA.
Peter R CarrollDepartment of Urology, University of California San Francisco, San Francisco, CA, USA.
Courtney Lawhn-HeathDepartments of Radiology and Biomedical Imaging and Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, USA.
Ken HerrmannDepartment of Molecular and Medical Pharmacology, Ahmanson Translational Imaging Division, University of California Los Angeles, Los Angeles, CA, USA.
Johannes CzerninDepartment of Molecular and Medical Pharmacology, Ahmanson Translational Imaging Division, University of California Los Angeles, Los Angeles, CA, USA.
Thomas A HopeDepartments of Radiology and Biomedical Imaging and Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, USA.
University of California, Los Angeles · USUniversity of California, San Francisco · US

Funding

MELT: Modulation of PSMA Expression for Lutetium TherapyR01CA235741 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HOPE, THOMAS A · 2019 to 2025
$3.2M
Qualification and Harmonization of PET/MRI for Cancer Clinical TrialsR01CA212148 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HOPE, THOMAS, LAFOREST, RICHARD ANDRE · 2017 to 2022
$2.7M
Immunogenic Priming with Lu-PSMA Targeted Therapy in Advanced Prostate CancerR01CA229354 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI AGGARWAL, RAHUL, HOPE, THOMAS · 2019 to 2020
$735k
NCI NIH HHS R01 CA212148NCI NIH HHS R01 CA229354NCI NIH HHS R01 CA235741
6 · The paper itself

Abstract

purposeReaders need to be informed about potential pitfalls of [

methodsHere we report [

resultsConsensus reads were false positive in 20 regions of 17/217 (8%) patients with lesion validation. Majority of the false positive interpretations (13 of 20, 65%) occurred in the context of suspected prostate (bed) relapse (T) after radiotherapy (n = 11); other false positive findings were noted for prostate bed post prostatectomy (T, n = 2), pelvic nodes (N, n = 2), or extra pelvic lesions (M, n = 5). Major sources of false positive findings were PSMA-expressing residual adenocarcinoma with marked post-radiotherapy treatment effect. False negative interpretation occurred in 8 regions of 6/79 (8%) patients with histopathology validation, including prostate (bed) (n = 5), pelvic nodes (n = 1), and extra pelvic lesions (n = 2). Lesions were missed mostly due to small metastases or adjacent bladder/urine uptake.

conclusion[ TRIAL REGISTRATION NUMBER: ClinicalTrials.gov Identifiers: NCT02940262 and NCT03353740.

Indexed as

ProstateProstatic NeoplasmsEdetic AcidHumansMaleNeoplasm Recurrence, LocalPositron Emission Tomography Computed TomographyProspective StudiesProstatectomyEdetic AcidInterpretationPETPitfallPSMARadiotherapyRecurrence

Identifiers

PMID32808077
PMCPMC7835157
OpenAlexW3050429624

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.